NIH: Translating Biomaterials-Based Technologies to Commercially Viable Products

NIH: Translating Biomaterials-Based Technologies to Commercially Viable Products

05sep11:59 pmNIH: Translating Biomaterials-Based Technologies to Commercially Viable ProductsFocused on technologies leading to commercialized products

Event Details

Notice of Special Interest: Translating Biomaterials-Based Technologies to Commercially Viable Products (NOT-EB-24-001)

The NHLBI is now participating a Notice of Special Interest (NOSI) for SBIR/STTR applications focused on advancing paradigm-shifting biomaterials-based technologies leading to commercialized products.   Additionally, this NOSI aims to generate private-sector interest and engagement in the development of innovative and emerging biomaterials-based technologies of biomedical and clinical relevance with high commercialization potential. Examples of topics of interest within the scope of this NOSI include but are not limited to:

  • AI- mediated design and manufacturing of biomaterials for HLBS-specific indications
  • Tissue organoids, Organ-on-a-chip systems, and in vitro models for the screening/identification of novel therapeutics and diagnostics for HLBS diseases
  • Immunomodulatory biomaterials to facilitate tissue repair and regeneration in HLBS diseases
  • Integration of nanotechnology for targeted drug delivery to treat HLBS diseases
  • Creating biomaterial environments optimized for the growth, differentiation, and delivery of stem cells for HLBS therapies
  • Development of biomaterials (or coatings) that are optimized for long-term use in wearable devices or implants for monitoring or treating HLBS disorders without inflicting an adverse immune response or inflammation
  • Development of biomedical products that can be used to improve sleep disorders, such as sleep apnea
  • Design of novel, portable biomedical products for draining, posttraumatic, and post-surgical empyema as well as for discharging pleural effusions
  • Novel biomaterial-based sensors that provide a readout of normal or disease-affected physiological states
  • Design of materials that prevent blood clotting, which can be used in various medical devices like catheters or stents
  • Biomaterials designed to enhance vascularization of tissues for HLBS conditions
  • New biomaterials that may be used to replace or supplement whole blood or blood products for transfusion medicine

 For more information, please visit


(Thursday) 11:59 pm(GMT-04:00)